EMUGEN

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 31 Mar 2026 filing date already counts against anyone who files later.

Record

Serial number

99735877

Mark type

Word mark

Filed

31 Mar 2026

Published for opposition

08 Sept 2026

Attorney of record

Karen K. Won

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations, namely, gene therapy products for the treatment of Rett Syndrome, Dravet Syndrome, neurological diseases and disorders, central nervous system disease and disorders, and genetic diseases and disorders; Pharmaceutical preparations for gene replacement and gene regulation in diseases, disorders, and conditions affecting the brain and central nervous system; Drug delivery agents, namely, bioengineered adeno-associated virus vectors for delivering gene therapies across blood-brain barrier
• Class 042 — Scientific and technological services: Scientific research and development of new technologies and products in the field of gene therapy, neurology, neurobiology, and genetic medicine; Bioengineering of adeno-associated virus vectors for use in gene therapy, and other gene regulation and gene replacement technologies; Providing scientific research information in the field of gene therapy, neurology, neurobiology, genetic medicine, and drug delivery across blood-brain barrier

Owner

• Emugen Therapeutics LLC, Woburn, MA, US
• Emugen Therapeutics LLC, Woburn, MA, US

Prosecution history

• 03 Nov 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 08 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 08 Sept 2026 — PUBLISHED FOR OPPOSITION
• 02 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 11 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 11 Aug 2026 — ASSIGNED TO EXAMINER
• 29 Jul 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 31 Mar 2026 — APPLICATION FILING RECEIPT MAILED
• 31 Mar 2026 — NEW APPLICATION ENTERED